These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19875563)

  • 1. Early insulin use in type 2 diabetes: what are the cons?
    Chiasson JL
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S270-4. PubMed ID: 19875563
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
    Riddle MC
    Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.
    Halimi S
    Diabetes Metab; 2015 Apr; 41(2):105-6. PubMed ID: 25824635
    [No Abstract]   [Full Text] [Related]  

  • 4. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Arnolds S; Rave K
    Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
    Vos RC; Rutten GEHM
    JAMA; 2017 Oct; 318(15):1489-1490. PubMed ID: 29049639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A summary of the ADVANCE Trial.
    Heller SR;
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
    [No Abstract]   [Full Text] [Related]  

  • 7. United Kingdom prospective diabetes study: a different perspective.
    Kabadi UM
    Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing potential glycemic overtreatment in persons at hypoglycemic risk.
    Tseng CL; Soroka O; Maney M; Aron DC; Pogach LM
    JAMA Intern Med; 2014 Feb; 174(2):259-68. PubMed ID: 24322626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Type 2 diabetes: hypoglycemia risk, weight gain... Will there soon be a new alternative to insulin?].
    MMW Fortschr Med; 2006 Sep; 148(37):54. PubMed ID: 17036907
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hypoglycemia--simply annoying or dangerous?].
    Kern W
    MMW Fortschr Med; 2016 Jun; 158(11):67-70. PubMed ID: 27271419
    [No Abstract]   [Full Text] [Related]  

  • 11. Starting insulin therapy in type 2 diabetes: lesson 1.
    McCall AL
    Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin therapy for type 2 diabetes.
    Swinnen SG; Hoekstra JB; DeVries JH
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S253-9. PubMed ID: 19875560
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
    Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
    CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC; Schneider J
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tough glucose reduction necessary in newly diagnosed diabetes].
    Rydén M
    Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
    Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
    J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 18. [SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Nauck M; Del Prato S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S4-5. PubMed ID: 23529569
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of non-insulin-dependent diabetes mellitus.
    Davidson MB
    Mayo Clin Proc; 1997 Jan; 72(1):92. PubMed ID: 9005295
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
    Dills DG; Schneider J
    Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.